In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clarins

This article was originally published in The Rose Sheet

Executive Summary

Self Tanning Face Lotion SPF 15 debuting in Light Tan and Deep Tan formulas. Stabilized DHA and eurythrulose react with skin's amino acids to create "a more natural, even and longer-lasting tan" within two hours, Clarins claims. Along with sunscreens such as octyl methoxycinnamate, the product contains Clarins' exclusive triactitan complex of oat and bran extracts, vitamins and botanicals that is said to help prevent premature sunburn. In addition, tyrosine accelerates "the tanning process while reinforcing skin's natural protection." A 50 mL orange pump-top bottle with metallic gold sunburst icon will retail for $23. At launch, Clarins will provide 750,000 samples for customers. An ad campaign to support the firm's sunless tanning products will run in April and May beauty books including Vogue, Marie Claire, InStyle and W

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel